Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/23
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/23
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAEGlobeNewsWire • 06/26/23
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023GlobeNewsWire • 06/10/23
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should KnowZacks Investment Research • 05/17/23
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/23
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema WorkshopGlobeNewsWire • 05/06/23
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 04/05/23
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APACGlobeNewsWire • 03/18/23
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual MeetingGlobeNewsWire • 02/24/23
Pharvaris shares soar on positive top-line Phase 2 data from RAPIDe-1 study as it releases 3Q resultsProactive Investors • 12/08/22